A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer

A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer

Purpose This study investigated the safety and clinical activity of lumretuzumab, a humanised antihuman epidermal growth factor receptor 3 (HER3) monoclonal antibody, in combination with carboplatin and paclitaxel in first-line treatment of patients with squamous non-small cell lung cancer (sqNSCLC)...

Full description

Bibliographic Details
Main Authors: Enriqueta Felip, Juan-Miguel Cejalvo, Wolfgang Jacob, Tania Fleitas Kanonnikoff, Alejandro Navarro Mendivil, Maria Martinez Garcia, Alvaro Taus Garcia, Natasha Leighl, Ulrik Lassen, Morten Mau-Soerensen, Celine Adessi, Francesca Michielin, Ian James, Maurizio Ceppi, Max Hasmann, Martin Weisser
Format: Article
Language:English
Published: Elsevier 2019-07-01
Series:ESMO Open
Online Access:https://esmoopen.bmj.com/content/4/4/e000532.full

Internet

https://esmoopen.bmj.com/content/4/4/e000532.full

Similar Items